donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NVO Novo-Nordisk A/S > Company Executives
NVO Novo-Nordisk A/S
111.640
+0.210+0.19%
Post Mkt Price
111.64000.00%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Lars Fruergaard JorgensenChief Executive Officer and President------54male02/02/2022
Mr. Karsten KnudsenExecutive Vice President and Chief Financial Officer17.20M----50male02/02/2022
Mr. Marcus Schindler, PhDExecutive Vice President, Head of Research & Early Development and Chief Scientific Officer------55male02/02/2022
Mr. Maziar Mike DoustdarExecutive Vice President and Head of International Operations------51male02/02/2022
Mr. Henrik Ehlers WulffExecutive Vice President and Head of Product Supply, Quality & IT19.60M----51male02/02/2022
Ms. Camilla SylvestExecutive Vice President and Head of Commercial Strategy and Corporate Affairs17.30M----49female02/02/2022
Mr. Doug LangaExecutive Vice President and Head of North America Operations------55male02/02/2022
Ms. Monique CarterExecutive Vice President and Head of People and Organisation6.00M----48female02/02/2022
Mr. Ludovic HelfgottExecutive Vice President and Head of Biopharm------47male02/02/2022
Mr. Martin Holst LangeExecutive Vice President and Head of Development------51male02/02/2022
Mr. Helge LundChairman of the Board3.10M----59male02/02/2022
Mr. Jeppe ChristiansenVice Chairman of the Board1.90M----62male02/02/2022
Ms. Anne Marie KvernelandDirector1.00M----65female02/02/2022
Mr. Stig StrobaekDirector1.20M----58male02/02/2022
Mr. Henrik PoulsenDirector------54male02/02/2022
Mr. Kasim KutayDirector1.00M----56male02/02/2022
Ms. Mette Bojer JensenDirector1.00M----46female02/02/2022
Mr. Thomas RantzauDirector------49male02/02/2022
Dr. Martin W. Mackay, PhDIndependent Director1.40M----65male02/02/2022
Dr. Sylvie Gregoire,Pharm.D.Independent Director1.70M----60female02/02/2022
Ms. Laurence DebrouxIndependent Director1.10M----52female02/02/2022
Mr. Andreas FibigIndependent Director1.40M----59male02/02/2022
Company Overview More
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
CEO: Jorgensen, Lars Fruergaard
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...